TENAX THERAPEUTICS ($TENX) posted quarterly earnings results for Q1 2026 on Tuesday, May 12th. The company reported earnings of -$0.35 per share, beating estimates of -$0.41 by $0.06. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $TENX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TENAX THERAPEUTICS Insider Trading Activity
TENAX THERAPEUTICS insiders have traded $TENX stock on the open market 13 times in the past 6 months. Of those trades, 13 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TENX stock by insiders over the last 6 months:
- STUART RICH (Chief Medical Officer) has made 5 purchases buying 10,000 shares for an estimated $96,414 and 0 sales.
- THOMAS MCGAULEY (Interim CFO) has made 3 purchases buying 8,000 shares for an estimated $58,164 and 0 sales.
- CHRISTOPHER THOMAS GIORDANO (CEO) has made 3 purchases buying 2,605 shares for an estimated $19,999 and 0 sales.
- JUNE SHERIE ALMENOFF has made 2 purchases buying 1,993 shares for an estimated $14,944 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
TENAX THERAPEUTICS Hedge Fund Activity
We have seen 30 institutional investors add shares of TENAX THERAPEUTICS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC added 439,142 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,353,140
- VR ADVISER, LLC removed 437,708 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,335,660
- POINT72 ASSET MANAGEMENT, L.P. added 423,415 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,161,428
- MORGAN STANLEY added 418,047 shares (+234.4%) to their portfolio in Q4 2025, for an estimated $5,095,992
- UBS GROUP AG added 380,743 shares (+56322.9%) to their portfolio in Q1 2026, for an estimated $6,088,080
- DIADEMA PARTNERS LP added 243,170 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,964,242
- SPHERA FUNDS MANAGEMENT LTD. added 190,111 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,317,453
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
TENAX THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $TENX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 12/17/2025
To track analyst ratings and price targets for TENAX THERAPEUTICS, check out Quiver Quantitative's $TENX forecast page.
TENAX THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $TENX recently. We have seen 2 analysts offer price targets for $TENX in the last 6 months, with a median target of $34.5.
Here are some recent targets:
- Olivia Brayer Saunders from Cantor Fitzgerald set a target price of $35.0 on 03/17/2026
- Seamus Fernandez from Guggenheim set a target price of $34.0 on 03/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
